美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Eikon Therapeutics

12.35

+1.1910.66%

成交量：29.27萬

成交額：349.18萬

市值：6.67億

市盈率：-2.08

高：12.38

開：11.26

低：11.24

收：11.16

52周最高：17.40

52周最低：7.90

股本：5,398.43萬

流通股本：1,764.80萬

量比：0.66

換手率：1.66%

股息：- -

股息率：- -

每股收益(TTM):-5.9500

每股收益(LYR):-115.2900

淨資產收益率：-125.02%

總資產收益率：-36.19%

市淨率：1.43

市盈率(LYR):-0.11

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發

深圳商报·读创

Eikon Therapeutics宣佈晚期黑色素瘤Eik1001適應症2/3期試驗Teluride-006進入劑量選擇階段

Eikon Therapeutics宣佈Teluride-008臨床試驗首位患者給藥，Eik1001用於非小細胞肺癌的註冊性II/III期研究正式啓動

新聞稿：Eikon Therapeutics 宣佈任命 Ma. Fatima D. Francisco 加入董事會

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/EIKN"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"EIKN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","market":"US","secType":"STK","nameCN":"Eikon Therapeutics","latestPrice":12.35,"timestamp":1787678748632,"preClose":11.16,"halted":0,"volume":292723,"delay":0,"changeRate":0.10663082437275981,"floatShares":17648000,"shares":53984300,"eps":-5.95,"marketStatus":"交易中","change":1.19,"latestTime":"08-25 13:25:52 EDT","open":11.26,"high":12.38,"low":11.24,"amount":3491838.8059679996,"amplitude":0.102151,"askPrice":12.43,"askSize":100,"bidPrice":12.27,"bidSize":227,"shortable":3,"etf":0,"ttmEps":-5.95,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1770267600000,"exchange":"NASDAQ","adjPreClose":11.16,"preHourTrading":{"tag":"盘前","latestPrice":11.83,"preClose":11.16,"latestTime":"09:25 EDT","volume":54,"amount":638.82,"timestamp":1787664300069,"change":0.67,"changeRate":0.060036,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.16,"preClose":11.16,"latestTime":"19:30 EDT","volume":2031,"amount":22653.6328,"timestamp":1787614205064,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.663453},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EIKN\",,,,,undefined,":{"symbol":"EIKN","floatShares":17648000,"roa":"-36.19%","roe":"-125.02%","lyrEps":-115.29,"volumeRatio":0.663453,"shares":53984300,"dividePrice":0,"high":12.38,"amplitude":0.102151,"preClose":11.16,"low":11.24,"week52Low":7.9,"pbRate":"1.43","week52High":17.4,"institutionHeld":0,"latestPrice":12.35,"committee":0.388379,"eps":-5.95,"divideRate":0,"volume":292723,"delay":0,"ttmEps":-5.95,"open":11.26,"prevYearClose":18,"prevWeekClose":11.39,"prevMonthClose":9.21,"prevQuarterClose":13.05,"fiveDayClose":11.65,"twentyDayClose":9.49,"sixtyDayClose":10.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EIKN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"EIKN","fiscalQuarterEnding":"2026/06","expectedEps":-1.61,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.63},{"market":"US","date":"2026-05-11","symbol":"EIKN","fiscalQuarterEnding":"2026/03","expectedEps":-1.47,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-2.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EIKN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EIKN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.6667,"hold":0,"sell":0,"strongSell":0.1667,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1775102400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EIKN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EIKN","date":"2026-08-24","current":-2.07563,"percent":0.360294,"low":-3.139466,"twenty":-2.100934,"median":-1.723362,"eighty":-1.535213,"high":-1.335246,"avg":-1.859596,"sd":0.391079,"marketCap":616939691},"quantilePoints":[{"date":"2026-02-06","current":-2.616222,"twenty":-3.034817,"median":-2.877844,"eighty":-2.720871,"marketCap":809765055},{"date":"2026-02-13","current":-2.586571,"twenty":-2.610292,"median":-2.537735,"eighty":-2.527619,"marketCap":800587717},{"date":"2026-02-20","current":-2.703429,"twenty":-2.7418,"median":-2.616222,"eighty":-2.529014,"marketCap":836757223},{"date":"2026-02-27","current":-2.379017,"twenty":-2.703429,"median":-2.596164,"eighty":-2.52727,"marketCap":736346356},{"date":"2026-03-06","current":-2.535991,"twenty":-2.644128,"median":-2.595292,"eighty":-2.523782,"marketCap":784932259},{"date":"2026-03-13","current":-2.054606,"twenty":-2.624942,"median":-2.562153,"eighty":-2.406924,"marketCap":635935489},{"date":"2026-03-20","current":-1.915074,"twenty":-2.616222,"median":-2.529014,"eighty":-2.298787,"marketCap":592748020},{"date":"2026-03-27","current":-1.836588,"twenty":-2.600524,"median":-2.515933,"eighty":-2.054606,"marketCap":568455068},{"date":"2026-04-02","current":-1.678228,"twenty":-2.599129,"median":-2.426109,"eighty":-1.985189,"marketCap":544162116},{"date":"2026-04-10","current":-1.504368,"twenty":-2.597385,"median":-2.379017,"eighty":-1.821565,"marketCap":487788380},{"date":"2026-04-17","current":-1.876704,"twenty":-2.595641,"median":-2.269137,"eighty":-1.751381,"marketCap":608517358},{"date":"2026-04-24","current":-1.786542,"twenty":-2.595292,"median":-2.061583,"eighty":-1.769507,"marketCap":579282538},{"date":"2026-05-01","current":-1.605383,"twenty":-2.588315,"median":-2.045013,"eighty":-1.651966,"marketCap":520542206},{"date":"2026-05-08","current":-1.531083,"twenty":-2.547502,"median":-1.986901,"eighty":-1.641614,"marketCap":496450549},{"date":"2026-05-15","current":-2.105086,"twenty":-2.53634,"median":-1.963159,"eighty":-1.651966,"marketCap":713546154},{"date":"2026-05-22","current":-1.782455,"twenty":-2.530409,"median":-1.936811,"eighty":-1.659647,"marketCap":604186273},{"date":"2026-05-29","current":-1.645097,"twenty":-2.527968,"median":-1.929027,"eighty":-1.650964,"marketCap":557627116},{"date":"2026-06-05","current":-1.562046,"twenty":-2.525177,"median":-1.895889,"eighty":-1.633553,"marketCap":529475781},{"date":"2026-06-12","current":-1.360801,"twenty":-2.514363,"median":-1.841551,"eighty":-1.597703,"marketCap":461261110},{"date":"2026-06-18","current":-1.55406,"twenty":-2.482968,"median":-1.809917,"eighty":-1.567693,"marketCap":526768850},{"date":"2026-06-26","current":-1.573226,"twenty":-2.429947,"median":-1.776985,"eighty":-1.53713,"marketCap":533265485},{"date":"2026-07-02","current":-1.95655,"twenty":-2.406226,"median":-1.79823,"eighty":-1.541282,"marketCap":663198193},{"date":"2026-07-10","current":-1.79204,"twenty":-2.398552,"median":-1.809917,"eighty":-1.555657,"marketCap":607435406},{"date":"2026-07-17","current":-1.589198,"twenty":-2.377273,"median":-1.784498,"eighty":-1.563963,"marketCap":538679348},{"date":"2026-07-24","current":-1.536491,"twenty":-2.355995,"median":-1.761474,"eighty":-1.543838,"marketCap":520813601},{"date":"2026-07-31","current":-1.536491,"twenty":-2.298787,"median":-1.731347,"eighty":-1.536491,"marketCap":520813601},{"date":"2026-08-07","current":-1.471006,"twenty":-2.239486,"median":-1.715581,"eighty":-1.534894,"marketCap":498616763},{"date":"2026-08-14","current":-1.736786,"twenty":-2.116266,"median":-1.712181,"eighty":-1.534894,"marketCap":559524759},{"date":"2026-08-21","current":-1.807401,"twenty":-2.105086,"median":-1.719889,"eighty":-1.534894,"marketCap":582274072},{"date":"2026-08-24","current":-1.915004,"twenty":-2.100934,"median":-1.723362,"eighty":-1.535213,"marketCap":616939691}],"updateTime":1787678752686},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EIKN\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658911994","title":"營收暴增無阻英派藥業繼續虧損：預計上半年減虧三成左右！股價早已破發","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911994","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911994?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 23:03","pubTimestamp":1786460583,"startTime":"0","endTime":"0","summary":"8月11日，英派药业(07630.HK)发布盈利预告，公司预计2026年上半年收入约9470万元至1.16亿元，较去年同期约2520万元增长约276%至359%；预计期内亏损约8170万元至9990万元，较去年同期约1.29亿元减少约22%至37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838249182.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838249182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4139","07630","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143932807","title":"Eikon Therapeutics宣佈晚期黑色素瘤Eik1001適應症2/3期試驗Teluride-006進入劑量選擇階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1143932807","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143932807?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447878,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日对外披露，其针对晚期黑色素瘤开展的在研药物Eik1001，已正式进入一项名为Teluride-006的适应性2/3期临床试验的剂量选择阶段。这一里程碑标志着该研究方案向前迈出了关键一步。Eikon Therapeutics专注于开发创新疗法，以攻克难治性癌症。此次剂量选择的宣布，体现了公司对于严谨临床试验流程的坚守，以及对加速推进Eik1001临床开发进度的决心。市场分析人士正密切关注这一进展，因为若试验结果积极，Eik1001有望为晚期黑色素瘤患者群体带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EIKN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181280733","title":"Eikon Therapeutics宣佈Teluride-008臨床試驗首位患者給藥，Eik1001用於非小細胞肺癌的註冊性II/III期研究正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1181280733","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181280733?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 19:32","pubTimestamp":1785151940,"startTime":"0","endTime":"0","summary":"Eikon Therapeutics今日宣布，其在研药物Eik1001的注册性II/III期临床试验——Teluride-008，已完成首位患者给药。这项研究专注于非小细胞肺癌（NSCLC）的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116184350","title":"新聞稿：Eikon Therapeutics 宣佈任命 Ma. Fatima D. Francisco 加入董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1116184350","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116184350?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 20:04","pubTimestamp":1780920252,"startTime":"0","endTime":"0","summary":"加州米尔布雷，2026年6月8日——致力于开发创新药物以解决严重未满足医疗需求的后期临床生物制药公司 Eikon Therapeutics, Inc.  今日宣布，任命 Ma. FatimaD. Francisco 女士为公司董事会独立董事，自2026年6月15日起生效。Francisco 女士还将担任董事会薪酬委员会成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/EIKN\",params:#limit:6,delay:false,,,undefined,":[]}}